131
da, dövmesi olmayanlarla karşılaştırıldığında dövmeli kişilerde HCV preva-
lansının daha yüksek olduğu bulunmuştur. Bu daha çok hijyenik koşullarda
yapılmayan, enfekte malzemelerle yapılan dövmelerde söz konusudur (4,25).
Kaynaklar
1.
Alter MJ. HCV routes of transmission: what goes around comes around. Semin
Liver Dis. 2011;31(4):340-6. doi: 10.1055/s-0031-1297923.
2.
Quer J, Esteban Mur JI.. Treatment of extrahepatic diseases caused by hepatitis B
and hepatitis C viruses. Tomas CH, Lemon S, Zuckerman AJ (edit) In viral hepatitis.
Blacwell Publishing, Third edition, UK 2005: 407-425.
3.
Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26(3 Suppl 1):62S-65S.
4.
Cacopardo B, Russo R, Fatuzzo F, Cosentino S, Lombardo T, La Rosa R, et al.
HCV and HBV infection among multitransfused thalassemics from eastern Sicily..
Infection. 1992; 20(2):83-5.
5.
Locasciulli A, Gornati G, Tagger A, Ribero ML, Cavalletto D, Cavalletto L, et al.
Hepatitis C virus infection and chronic liver disease in children with leukemia in
long-term remission. Blood. 1991;78(6):1619-22.
6.
HCV routes of transmission: what goes around comes around. Alter MJ. Semin
Liver Dis. 2011;31(4):340-6. doi: 10.1055/s-0031-1297923.
7.
McIntyre PG, McCruden EA, Dow BC, Cameron SO, McMillan MA, Allison ME et
al. Hepatitis C virus infection in renal dialysis patients in Glasgow. Nephrol Dial
Transplant. 1994;9(3):291-5.
8.
Fujiyama S, Kawano S, Sato S, Shimada H, Matsushita K, Ikezaki N, Nakano T,
Sato T. Changes in prevalence of anti-HCV antibodies associated with preventive
measures among hemodialysis patients and dialysis staff. Hepatogastroenterology
1995 ; 42(2):162-5.
9.
Norol F, Roche B, Girardin MF, Kuentz M, Desforges L, Cordonnier C, Duedari N,
Vernant JP. Hepatitis C virus infection and allogeneic bone marrow transplantation.
Transplantation. 1994;57(3):393-7
10.
Gates JA, Post JJ, Kaldor JM, Pan Y, Haber PS, Lloyd AR, Dolan KA; Hepatitis C
Incidence and Transmission in Prison Study Group. Risk factors for hepatitis C
infection and perception of antibody status among male prison inmates in the
Hepatitis C Incidence and Transmission in Prisons Study cohort, Australia J Urban
Health. 2004;81(3):448-52.
11.
Reker C, Islam KM Risk factors associated with high prevalence rates of hepatitis C
infection in Egypt. Int J Infect Dis. 2014;25:104-6. doi: 10.1016/j.ijid.2014.02.003.
12.
Gigi E, Sinakos E, Sykja A, Androulakis G, Tanis C, Stayridou V, et al. Epidemiology,
clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug
users. J Addict Med. 2013;7(1):52-7. doi: 10.1097/ADM.0b013e318279756f.
13.
Matheï C, Buntinx F, van Damme P. Seroprevalence of hepatitis C markers among
intravenous drug users in western European countries: a systematic review.. J
Viral Hepat. 2002;9(3):157-73.
14.
Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L. Monitoring hepatitis
C virus infection among injecting drug users in the European Union: a review of
the literature.Epidemiol Infect. 2002;129(3):577-85.
Hepatit C Enfeksiyonunda Bulaşma Yolları
